This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Gotto, A. M. Articles by Grundy, S. M. Search for Related Content PubMed PubMed Citation Articles by Gotto, A. M., Jr Articles by Grundy, S. M.

(Circulation. 1999;99:E1-E7.)
© 1999 American Heart Association, Inc.

Circulation Electronic Pages

Lowering LDL Cholesterol

Questions From Recent Meta-Analyses and Subset Analyses of Clinical Trial DataIssues From the Interdisciplinary Council on Reducing the Risk for Coronary Heart Disease, Ninth Council Meeting

Antonio M. Gotto, Jr, MD, DPhil; Scott M. Grundy, MD, PhD

From Cornell University Medical College (A.M.G.), New York, NY, and the Center for Human Nutrition at The University of Texas Southwestern Medical Center (S.M.G.), Dallas, Tex.

Correspondence to Antonio M. Gotto, Jr, MD, DPhil, Dean, Cornell University Medical Center, 1300 York Ave, New York, NY 10021. E-mail dean{at}mail.med.cornell.edu

Abstract

Abstract—The benefit of cholesterol-lowering therapy in the prevention of coronary heart disease (CHD) is well established. The secondary prevention Scandinavian Simvastatin Survival Study (4S) and the primary prevention West of Scotland Coronary Prevention Study (WOSCOPS) demonstrated that lipid lowering with a statin can dramatically and cost-effectively reduce CHD morbidity and mortality with no increase in noncardiovascular mortality. The Cholesterol and Recurrent Events (CARE) trial extended benefit to CHD patients without high cholesterol. Post hoc analyses of data from these large trials are contributing to speculation, driven by subset analyses and meta-analyses, about whether cholesterol intervention should be target based, as current guidelines recommend. Whereas CARE data support the importance of baseline LDL cholesterol (LDL-C), with greatest clinical event risk reduction in the upper part of the LDL-C range in the trial, 4S found no difference in outcome according to baseline LDL-C in a quartile analysis, and WOSCOPS found no linear relation between decrease in LDL-C and decrease in relative risk for CHD. Furthermore, WOSCOPS showed no additional clinical benefit with LDL-C lowering beyond 24%. Questions raised by such analyses require answers from prospective, hypothesis-based data, and at present there is no compelling argument for moving away from LDL-C targets. The hypothesis-based findings of 4S, CARE, and WOSCOPS support current clinical guidelines, and lowering LDL-C may reduce risk more substantially than might have been predicted.

Key Words: cholesterol • coronary disease • lipoproteins • prevention